Last reviewed · How we verify
anti TNF alpha agent
At a glance
| Generic name | anti TNF alpha agent |
|---|---|
| Also known as | Infliximab - REMICADE as brand name, Etanercept- ENBREL as brand name |
| Sponsor | All India Institute of Medical Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Back pain
- Rheumatoid arthritis
- Gastrointestinal related
- Vitamin D deficiency
- Upper respiratory tract infection
- Hypertension
- Urinary tract infection
- Fatigue
- Chest pain
- Rash
- Other events
Key clinical trials
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
- Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (PHASE3)
- Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (PHASE4)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH) (PHASE4)
- Post-Operative Crohn's Disease Outcome in Children
- Adalimumab in JIA-associated Uveitis Stopping Trial (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |